Navigation Links
Stemline Therapeutics' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
Date:11/8/2012

ine Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. In a multicenter Phase 1/2 trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:

Mark Jacobson
Director, Corporate Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Sixth Floor
New York, NY 10022
Tel: 646-502-2307
Email: mjacobson@stemline.com
www.steml
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015 The American Society of ... Practice Guideline for the Use of Medications in the ... ).  The Practice Guideline will assist clinicians ... use. It addresses knowledge gaps about the benefits of ... evidence-based coverage standards by payers. The ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. The delivery of drugs ... in the treatment of neurological disorders. Drugs may ... systematically (e.g., by intravenous injection) for targeted action ...
(Date:6/2/2015)... and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ) has announced the addition of ... report to their offering. The report provides ... , Japan , Europe ... , and Rest of World. This report ... Million by the following Product Segments: Stapler Products (Internal Stapler, ...
Breaking Medicine Technology:American Society of Addiction Medicine Releases National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use 2American Society of Addiction Medicine Releases National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use 3Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Surgical Incision Closures - Global Strategic Business Report 2015 2
... May 5 A voluntary recall has,been issued ... and,labeled with the Cardinal Health brand name. Hydrox ... individual mouthwash bottles and,those contained within Cardinal Health ... and been found positive for Burkholderia,cepacia (B. cepacia). ...
... Delivered Within Pre-Determined ... and Standard Dosing Limitations, BRIDGEWATER, N.J., May 5 ... SoloSTAR(R) disposable insulin pen,prefilled with Lantus(R) (insulin glargine [rDNA ... the pens,accurately delivered all insulin doses within standard limits ...
Cached Medicine Technology:Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:6/2/2015)... 02, 2015 On Wednesday, May 27, 2015, ... to a top speed of 207.9 mph. In the ... to break the 200 mph mark. Jay Leno was ... upcoming episode of Jay Leno’s Garage, which will air on ... the 8.5 mile high speed oval at the Continental Tire ...
(Date:6/2/2015)... UCLA Health and Exer have completed ... and expand urgent care services in Los Angeles County. ... University of California Board of Regents and the Exer ... Health to purchase a minority share of four existing ... Park and Northridge and creates opportunity to grow and ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 TMG Health, ... for health plans in the Medicare Advantage, Medicare Part ... a sponsor and exhibitor at AHIP’s Institute 2015, the ... Insurance Plans. The conference will be held June 3-5 ... #1303, will offer opportunities for attendees to schedule private ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 On October ... congressional efforts for another delay. , On Monday, ... Health Subcommittee for the House Ways and Means Committee, ... to Centers for Medicare and Medicaid Services, urging the ... as CMS rolls out ICD-10. ICD-10 is the newest ...
(Date:6/2/2015)... 02, 2015 IMPAK Corporation, a ... has announced the availability of “child-resistant” pouches and ... by children, especially curious toddlers. The Child Resistant ... tested to CFR 1700.20 protocols. The announcement was ... Looks Like Candy, “With the proliferation of consumer ...
Breaking Medicine News(10 mins):Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... , , CHADDS FORD, Pa., Aug. 31 ... at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, ... review the company,s products and development programs. , , The ... www.endo.com under the investors section. , ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... say , MONDAY, Aug. 31 (HealthDay News) -- Mass screening ... has led to mass over-diagnosis and over-treatment, a new study ... in 1986, federal government data show that the number of ... said the report in the Aug. 31 online issue of ...
... , MONDAY, Aug. 31 (HealthDay News) -- Walk-in retail clinics ... a new study has found. , Writing in the Sept. ... study author Dr. Ateev Mehrotra said that retail clinics -- ... drug stores and other retail chain stores such as Target ...
... , ABBOTT PARK, Ill., Aug. 31 ... Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009. ... will make a presentation on the company at 8:10 a.m. Central ... the presentation will be accessible through Abbott,s Investor Relations Web site ...
... , Safety tips also offered as fires threaten ... The American Red Cross is on the scene offering evacuees a safe ... and scorch thousands of acres. Overnight, nearly 200 people took refuge from ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: